Loading...
Market
Alumis market cap surpasses $1 billion by mid-2025?
5
Resolution / Starting Odds
Yes • 50%
No • 50%
Nasdaq or major financial news outlets
Story
Alumis Prices Downsized IPO at $16 Per Share, Raises $250 Million, Valued at $902 Million
Jun 28, 2024, 04:50 AM
Alumis, an immunology biotech company, has announced the pricing of its initial public offering (IPO) at $16 per share, the low end of its marketed range of $16 to $18. The company initially planned to offer 17.65 million shares but downsized the offering to 13.125 million shares. The IPO raised $250 million, which is below its initial target of $300 million. The funds will be used to support the company's TYK2 inhibitor through phase 3 psoriasis trials and a late-stage psoriasis clinical trial. The IPO values Alumis at approximately $902 million, which is lower than the previously anticipated $1 billion valuation. The company also conducted a concurrent private placement. Notably, the IPO amount is slightly below its last VC round of $259 million. Alumis is now NasdaqListed.
View original story
Similar markets
Less than $500 million • 33%
$500 million to $1 billion • 34%
More than $1 billion • 33%
Increased by more than 50% • 33%
Increased by 0-50% • 34%
Decreased • 33%
Less than $1 billion • 25%
$1 billion to $5 billion • 25%
$5 billion to $10 billion • 25%
More than $10 billion • 25%
Increase by more than $20 billion • 25%
Increase by $10 billion to $20 billion • 25%
Increase by less than $10 billion • 25%
Decrease • 25%
